Oct 03rd 2013 - Edison Investment Research today published a report on GW Pharmaceuticals (GWP.L, LSE:GWP, LON:GWP) entitled "ADR Update: Steps Forward In MS Spasticity". In summary, the report says:
The commercial prospects for Sativex in MS spasticity have improved in the US and EU. Partner Almirall has resolved the German pricing issue and achieved acceptable reimbursement in Europe’s largest MS market. In the US, the opening of an IND paves the way for a pivotal Phase III study starting H214. Including these opportunities increases our Sativex peak sales by $149m to $820m. Our valuation rises to $378m.
Edison Investment Research is a leading international investment research company. It has won industry recognition, with awards both in the UK and internationally. The team of 95 includes over 60 analysts supported by a department of supervisory analysts, editors and assistants. Edison writes on more than 400 companies across every sector and works directly with corporates, fund managers, investment banks, brokers and other advisers. Edison’s research is read by institutional investors, alternative funds and wealth managers in more than 100 countries. Edison, founded in 2003, has offices in London, New York and Sydney and is authorised and regulated by the Financial Services Authority (www.fsa.gov.uk/register/firmBasicDetails.do?sid=181584). more »